Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction-Reference-Cited by-同舟云学术

Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction

Published:2020-06-24 Issue:1 Volume:27 Page:219-234
ISSN:1382-4147
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Nashawi Mouhamed^ORCID,Sheikh Omar,Battisha Ayman,Mir Mahnoor,Chilton Robert

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10741-020-09996-y.pdf

Reference154 articles.

1. Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH (2009) Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol 8(1):53

2. Andersson C, Vasan RS (2014) Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin 10(3):377–388

3. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, Deswal A, Dickson VV, Kosiborod MN, Lekavich CL, McCoy R, Mentz RJ, Piña IL, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America (2019) Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 140(7):e294–e324

4. Kristensen SL, Jhund PS, Lee MMY et al (2017) Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther 31(5–6):545–549

5. Berthelot E, Montani D, Algalarrondo V, Dreyfuss C, Rifai R, Benmalek A, Jais X, Bouchachi A, Savale L, Simonneau G, Chemla D, Humbert M, Sitbon O, Assayag P (2017) A clinical and echocardiographic score to identify pulmonary hypertension due to HFpEF. J Card Fail 23(1):29–35

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NEW DIRECTIONS IN PHARMACOLOGICAL TREATMENT WITH SGLT-2 INHIBITOR MOLECULES IN THE LIGHT OF CURRENT GUIDELINES FOR DIABETES MELLITUS, HEART FAILURE AND KIDNEY DISEASE;FARMACIA;2023-08-31

2. Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia;Biomedicine & Pharmacotherapy;2022-10

3. Empagliflozin—A New Chance for Patients with Chronic Heart Failure;Pharmaceuticals;2021-12-30